Regulus Therapeutics reported $57.93M in Current Assets for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Assets Change
Alnylam Pharmaceuticals ALNY:US $ 2471.64M 118.04M
AstraZeneca AZN:LN 20.92B 1.73B
Astrazeneca AZN:US 20.92B 1.73B
Biogen BIIB:US $ 9740.9M 1825M
Celldex Therapeutics CLDX:US $ 390.7M 20.14M
Gilead Sciences GILD:US $ 13705M 1076M
GlaxoSmithKline GSK:LN 54.19B 25.2B
Intrexon XON:US $ 154.94M 1.69M
IONIS PHARMACEUT IONS:US $ 2253.12M 91.92M
Ligand Pharmaceuticals LGND:US $ 276.07M 188.68M
Omeros OMER:US $ 210.22M 37.67M
Regulus Therapeutics RGLS:US $ 57.93M 7.3M
Sangamo Biosciences SGMO:US $ 340.06M 58.7M
Spectrum Pharmaceuticals SPPI:US $ 93.18M 10.77M
Takeda 4502:JP Y 2549515M 44127M
Vital Therapies VTL:US $ 115.88M 10.89M
YTE INCY:US $ 3625.84M 337.75M